Routine laboratory tests to risk-stratify patients with chronic coronary artery disease

Journal of Cardiology

Volumn 61, Issue 2, 2013, Pages 132-137

  Sbrana, Francesco ^a   Cocci, Franca ^a,b   Papa, Angela ^a   Landi, Patrizia ^c   Sampietro, Tiziana ^a   Rossi, Giuseppe ^c   Rovai, Daniele ^a,c  

^a FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Chronic coronary heart disease; Laboratory tests; Prognosis

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; TRIACYLGLYCEROL;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEMATOCRIT; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LIOTHYRONINE BLOOD LEVEL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; BLOOD CELL COUNT; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHRONIC DISEASE; CORONARY ARTERY DISEASE; CREATININE; DIAGNOSTIC TESTS, ROUTINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEUTROPHILS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84873079599     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.09.005     Document Type: Article

References (38)

1. Fox K., Garcia M.A., Ardissino D., Buszman P., Camici P.G., Crea F., Daly C., De Backer G., Hjemdahl P., Lopez-Sendon J., Marco J., Morais J., Pepper J., Sechtem U., Simoons M., et al. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006, 27:1341-1381.
2. Harris M.I., Flegal K.M., Cowie C.C., Eberhardt M.S., Goldstein D.E., Little R.R., Wiedmeyer H.M., Byrd-Holt D.D. Prevalence of diabetes, impaired fasting glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998, 21:518-524.
3. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Materson B.J., Oparil S., Wright J.T., Roccella E.J. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
4. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary on the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment on high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
5. Gimelli A., Rossi G., Landi P., Marzullo P., Iervasi G., L'abbate A., Rovai D. Stress/rest myocardial perfusion abnormalities by gated SPECT: still the best predictor of cardiac events in stable ischemic heart disease. J Nucl Med 2009, 50:546-553.
6. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 309:499-502.
7. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
8. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
9. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
10. Culleton B.F., Larson M.G., Wilson P.W., Evans J.C., Parfrey P.S., Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999, 56:2214-2219.
11. Mann J.F., Gerstein H.C., Pogue J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
12. Iervasi G., Pingitore A., Landi P., Raciti M., Ripoli A., Scarlattini M., L'Abbate A., Donato L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003, 107:708-713.
13. Papa A., Emdin M., Passino C., Michelassi C., Battaglia D., Cocci F. Predictive value of elevated neutrophil-to-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta 2008, 395:27-31.
14. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
15. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
16. von Eckardstein A., Nofer J.R., Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001, 21:13-27.
17. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R., Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American Studies. Circulation 1989, 79:8-15.
18. McBride P.E. National Cholesterol Education Program. Perspectives: the NCEP ATP III guidelines-friend or foe? National Cholesterol Education Program. Prev Cardiol 2002, 5:152-155.
19. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001, 344:501-509.
20. Friberg L., Werner S., Eggertsen G., Ahnve S. Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina?. Arch Intern Med 2002, 162:1388-1394.
21. Coceani M., Iervasi G., Pingitore A., Carpeggiani C., L'Abbate A. Thyroid hormone and coronary artery disease: from clinical correlations to prognostic implications. Clin Cardiol 2009, 32:380-385.
22. Fontana M., Passino C., Poletti R., Zyw L., Prontera C., Scarlattini M., Clerico A., Emdin M., Iervasi G. Low triiodothyronine and exercise capacity in heart failure. Int J Cardiol 2012, 154:153-157.
23. Madjid M., Awan I., Willerson J.T., Casscells S.W. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004, 44:1945-1956.
24. Bickel C., Rupprecht H.J., Blankenberg S., Espiniola-Klein C., Schlitt A., Rippin G., Hafner G., Treude R., Othman H., Hofmann K.P., Meyer J. AtheroGene Investigators. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002, 89:901-908.
25. Azab B., Bhatt V.R., Phookan J., Murukutla S., Kohn N., Terjanian T., Widmann W.D. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol 2010, 106:470-476.
26. Uthamalingam S., Patvardhan E.A., Subramanian S., Ahmed W., Martin W., Daley M., Capodilupo R. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol 2011, 107:433-438.
27. Nikolsky E., Mehran R., Aymong E.D., Mintz G.S., Lansky A.J., Lasic Z., Negoita M., Fahy M., Pocock S.J., Na Y., Krieger S., Moses J.W., Stone G.W., Leon M.B., Dangas G. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. Am J Cardiol 2004, 94:1023-1027.
28. van Straten A.H., Hamad M.A., van Zundert A.J., Martens E.J., Schönberger J.P., de Wolf A.M. Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting: a comparison with the matched general population. Circulation 2009, 120:118-125.
29. Greenberg G., Assali A., Vaknin-Assa H., Brosh D., Teplitsky I., Fuchs S., Battler A., Kornowski R., Lev E.I. Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction. Am J Cardiol 2010, 105:435-440.
30. Muzzarelli S., Pfisterer M. TIME Investigators. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J 2006, 152:991-996.
31. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(5 Suppl. 3):S112-S119.
32. Shiba N., Shimokawa H. Chronic kidney disease and heart failure - bidirectional close link and common therapeutic goal. J Cardiol 2011, 57:8-17.
33. Hage F.G., Venkataraman R., Zoghbi G.J., Perry G.J., DeMattos A.M., Iskandrian A.E. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009, 53:2129-2140.
34. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., Lowe G.D., Pepys M.B., Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
35. Masaki Y., Shimada K., Kojima T., Miyauchi K., Inoue K., Kiyanagi T., Hiki M., Fukao K., Hirose K., Ohsaka H., Kume A., Miyazaki T., Ohmura H., Ohsaka A., Daida H. Clinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantation. J Cardiol 2011, 57:303-310.
36. Kume N., Mitsuoka H., Hayashida K., Tanaka M. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J Cardiol 2011, 58:38-45.
37. Steinberg B.A., Steg P.G., Bhatt D.L., Fonarow G.C., Zeymer U., Cannon C.P. REACH Registry Investigators. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol 2007, 99:1212-1215.
38. Boden W.E., O'Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J., Knudtson M., Dada M., Casperson P., Harris C.L., Chaitman B.R., Shaw L., Gosselin G., Nawaz S., Title L.M., et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356:1503-1516.